Atreca, Inc.
Save
3.57M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients.
Similar securities
Based on sector and market capitalization
Report issue